All three medications are approved by the FDA, but they have different doses and applications tailored to specific health conditions and populations.7 Other FDA approved GLP-1 receptor agonists for glycemic control include Dulaglutide SC (Trulicity), Exenatide injectable solution SC (Byetta), Exenatide injectable suspension SC, Liraglutide SC (Victoza), Liraglutide/insulin degludec (Xultophy), Lixisenatide/insulin glargine (Soliqua), and Tirzepatide (Mounjaro), which is also a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist
GHK-Cu (Copper Peptide) is a naturally occurring peptide complex extensively studied for its role in skin health, tissue regeneration, and cellular signalling
For example, our group conducted the first testing on tirzepatide, which is a GIP/GLP-1 receptor agonist that is now on the market and has been a big success
These include genes encoding antioxidants, cell rescue/defense proteins, and signaling proteins such as kinase, phosphatase, and transcription factors